EMA consults on regulatory acceptance of "3R" alternatives to animal studies
This article was originally published in SRA
The European Medicines Agency is seeking stakeholder feedback concerning the revision of its position on the replacement of animal studies with alternative models for drug testing1,2. The exercise, it is expected, will lead to the development of a clear process for the regulatory acceptance of all "3R" (replacement, reduction and refinement) alternative methods for non-clinical testing of medicinal products.
You may also be interested in...
The European Medicines Agency is developing a strategy to ensure that women have sufficient information to make informed choices about taking medicines during pregnancy and breastfeeding.
A first-of-its-kind collaborative study has found that real-world and natural history data are comparable to placebo data from clinical trials in Duchenne muscular dystrophy.
An EU group has listed several ambitious projects to help EU regulators realize their cherished vision of using big data capabilities to support innovation and public health. But these proposals may take a backseat as COVID-19-related challenges continue.